GiEnne Pharma

GiEnne Pharma is an Italian specialty pharmaceutical company dedicated to the commercialization of innovative therapies for rare and orphan diseases. Founded in 2004 and headquartered in Milan, the company focuses on high-unmet-need therapeutic areas such as oncology, hematology, and metabolic disorders. GiEnne Pharma operates primarily as a strategic partner for international biotechnology firms, providing the necessary infrastructure for market access and distribution within Italy. Their portfolio is characterized by advanced treatments, including several RNA interference (RNAi) therapies developed in collaboration with Alnylam Pharmaceuticals. The company plays a critical role in bringing life-changing medicines for conditions like hereditary transthyretin-mediated amyloidosis and acute hepatic porphyria to Italian patients.